2025-04-18
On March 5th, Nanolattix Group announced that its novel T320-ADC drug has received clinical trial approvals from the National Medical Products Administration (NMPA) of China, the U.S. Food and Drug Administration (FDA), and the Therapeutic Goods Administration (TGA) of Australia, marking a significant milestone in its global development journey.
As a proud R&D partner, Medicilon supported this milestone by delivering comprehensive preclinical services, covering efficacy studies, pharmacokinetics, and safety evaluations.
T320: A Highly Differentiated ADC Drug Targeting Solid Tumors
Designed to treat pancreatic, cervical, lung, and colorectal cancers, T320 stands out for its innovation and efficacy.
Key Highlights:
- High Efficacy: Demonstrated 92.3% tumor inhibition in pancreatic cancer models, outperforming current standards.
- Validated Safety: Showcased strong anti-tumor activity alongside a favorable safety profile.
- Global Recognition: Granted Orphan Drug Designation by the U.S. FDA for pancreatic cancer in May 2024.
Medicilon’s ADC Expertise: Powering the Future of Oncology Therapeutics
The approval of T320 highlights both leaderships of Nanolattix Group in ADC innovation and Medicilon capabilities in preclinical drug development.
Medicilon at a Glance:
- One-Stop ADC Platform: From payload synthesis and conjugation to IND-enabling pharmacology and safety evaluation.
- 440+ Tumor Models: Including over 118 PDX models, plus syngeneic, xenograft, and humanized tumor models.
- 28+ ADC Projects Approved: As of 2024, Medicilon has helped over 28 ADC candidates achieve clinical trial clearance, with 20+ more in the pipeline.
- Global Regulatory Compliance: Our > 310,000 sq ft GLP-certified lab supports IND submissions across the US, EU, Australia, and more, having contributed to 520+ IND approvals globally.
Medicilon congratulates Nanolattix Group on this major milestone. We remain committed to advancing global drug development and partnering with innovators to accelerate the future of oncology.
